|
Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release. |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |
Patents, Royalties, Other Intellectual Property - TeneoBio |
| |
|
|
| |
|
|
| |
|
|
| |
|
Consulting or Advisory Role - TeneoBio |
| |
|
Consulting or Advisory Role - TeneoBio |
| |
|
|
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
|
| |
|
Consulting or Advisory Role - TeneoBio |
| |
|
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio |
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst) |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |
Patents, Royalties, Other Intellectual Property - TeneoBio |